Acute Renal Failure with Amphotericin B in Lipid Emulsion

Annals of Pharmacotherapy

Volumn 30, Issue 9, 1996, Pages 1036-

  Gales, Mark a ^a   Gales, Barry j ^b   Alford, Kristina m ^c  

^a OKLAHOMA STATE UNIVERSITY   (United States)

^b SOUTHWESTERN OKLAHOMA STATE UNIVERSITY   (United States)

^c PARKLAND HEALTH AND HOSPITAL SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ITRACONAZOLE; LIPID EMULSION;

ACUTE KIDNEY FAILURE; ADULT; CASE REPORT; CLINICAL FEATURE; DOSE KIDNEY FUNCTION RELATION; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LETTER; NEPHROTOXICITY; PRIORITY JOURNAL; TORULOPSIS GLABRATA; URINARY TRACT INFECTION;

AMPHOTERICIN B; ANTIBIOTICS, ANTIFUNGAL; DRUG CARRIERS; DRUG THERAPY, COMBINATION; FAT EMULSIONS, INTRAVENOUS; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; KIDNEY FAILURE, ACUTE; MIDDLE AGED;

EID: 0029814837     PISSN: 10600280     EISSN: 15426270     Source Type: Journal    
DOI: 10.1177/106002809603000923     Document Type: Letter

References (10)

1. Anderson RP, Clark DA. Amphotericin B toxicity reduced by administration in fat emulsion. Ann Pharmacother 1995; 29: 496–500.
2. Leake HA, Appleyard MN, Hartley JPR. Successful treatment of resistant cryptococcal meningitis with amphotericin B lipid emulsion after nephrotoxicity with conventional intravenous amphotericin B. J Infect 1994; 28: 319–22.
3. Macedo MCMA, Dulley FL, Ostronoff M, Machado CM, Zambon E, Matsumoto C, et al. Effectiveness of amphotericin B in lipid emulsion for treating fungal septicemia in granulocytopenic patients (letter). Clin Infect Dis 1994; 19: 366–7.
4. Chavanet PY, Garry I, Charlier N, Caillot D, Kisterman JP, D'Athis M, et al. Trial of glucose versus fat emulsion in preparation of amphotericin for use in HIV infected patients with candidiasis. BMJ 1992; 305: 921–5.
5. Moreau P, Milpied N, Fayette N, Ramee JF, Harousseau JL. Reduced renal toxicity and improved clinical tolerance of amphotericin B mixed with Intralipid compared with conventional amphotericin B in neutropenic patients. J Antimicrob Chemother 1992; 30: 535–41.
6. Calliot D, Chavanet P, Casasnovas O, Solary E, Zanetta G, Buisson M, et al. Clinical evaluation of a new lipid-based delivery system for intravenous administration of amphotericin B. Eur J Clin Microbiol Infect Dis 1992;11:7–5.
7. Pascual B, Ayestaran A, Montoro JB, Oliveras J, Estibalez A, Julia A, et al. Administration of lipid-emulsion versus conventional amphotericin B in patients with neutropenia. Ann Pharmacother 1995; 29: 1197–201.
8. Thakur CP. Comparison of glucose versus fat emulsion in the preparation of amphotericin B for use in kala-azar. Trans R Soc Trop Med Hyg 1994; 88: 698–9.
9. Caillot D, Reny G, Solary E, Casasnovas O, Chavanet P, Bonnotte B, et al. A controlled trial of the tolerance of amphotericin B infused in dextrose or in Intralipid in patients with haematological malignancies. J Antimicrob Chemother 1994; 33: 603–13.
10. Trissel LA. Amphotericin B does not mix with fat emulsion (letter). Am J Health-Syst Pharm 1995; 52: 1463–4.